Home › Learn › GLP-1 Rebound Statistics

The Evidence, Plainly

The GLP-1 rebound: what the numbers actually say

You've probably seen the headline figure: most people regain much of their lost weight within a year of stopping a GLP-1. It comes from real research — but the number is often quoted without its context. Here's a plain-English look at what the studies show, what they don't, and why your own experience may differ.

Where the 60-70% figure comes from

Several clinical studies have followed people who lost weight on injectable GLP-1 medications and then stopped. A commonly cited finding is that participants regained roughly 60-70% of their lost weight within about a year of discontinuation. That range shows up often because it reflects results reported across more than one trial. It's a reasonable summary of what those studies observed — but it's an average drawn from specific groups under specific conditions, not a law that applies identically to everyone.

What the studies do show

• A clear average trend. Across the research, weight regain after stopping was common, and it typically began soon after the medication was discontinued.
• A direction, not just a magnitude. Many measures that improved during treatment — such as certain cardiometabolic markers — tended to move back toward starting points as weight returned.
• Consistency with the biology. The pattern lines up with what's known about appetite hormones and metabolic adaptation reasserting themselves once treatment ends.

What the numbers don't tell you

• They're averages, not individual forecasts. An average of 60-70% means some people regained far less and some regained more, including a portion who kept off a meaningful amount. A single percentage hides that spread.
• Study conditions may not match yours. Trial participants stopped abruptly and often without a structured maintenance plan. Real-world approaches — tapering, ongoing support, continued treatment in another form — differ from that design, and research on those alternatives is still developing.
• They rarely isolate any one factor. Weight is shaped by many things at once — starting point, how long someone was treated, lifestyle, health conditions, and more. Headline numbers usually can't tell you which factor drove which result.
• They can't promise your outcome. No study can tell any individual what will happen to them. That's a genuine limitation, not a loophole.

Why individual variation matters so much

The most important thing the averages leave out is you. Two people with the same starting weight can follow very different paths after stopping, depending on biology, circumstances, and the plan they put in place. This is exactly why researchers frame obesity as a chronic, relapsing condition and why many clinicians emphasize a deliberate maintenance phase. The statistics describe a tendency to regain in the absence of a plan — they don't describe what happens when there is one.

Turning the numbers into a decision

The practical takeaway isn't "regain is inevitable." It's that the phase after injections deserves attention before you reach it. Talking with a licensed provider — ideally before your last dose — lets you weigh nutrition, activity, ongoing check-ins, and, for some eligible patients, continued medication support in a different form. Needle-free, prescription-only options such as THIN™, a compounded semaglutide sublingual spray, exist for the maintenance phase and are dispensed only if a licensed provider determines they are appropriate. THIN™ is not FDA-approved.

Wondering how this applies to you? A short eligibility check is a free, no-pressure way to see whether a provider conversation makes sense.